Mursla Bio has announced a new collaboration with a leading global pharmaceutical company to support biomarker-guided drug development in metabolic dysfunction-associated steatohepatitis (MASH).
Eisai has presented new clinical data from a post-hoc sub-group analysis of the Clarity AD open-label extension for lecanemab at the 98th Congress of the German Society of Neurology in Berlin. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results